Most high income countries, including the UK, do not have a national prostate cancer screening programme, but instead allow men without symptoms to get a prostate-specific antigen (PSA) test if they wish, after talking to their doctor. But experts writing in The BMJ today argue that these shared decision policies have led to high rates of PSA testing and clear medical harm, with minimal benefit and inequity.